Veranex Purchases Preclinical Testing Firm T3 Labs

Veranex, an end-to-end medtech manufacturing partner, has acquired T3 Labs, an Atlanta-based preclinical laboratory.
 
T3 Labs boasts a 33,000-square-foot facility with equipment, training facilities, and operating rooms dedicated to research in 12 therapeutic areas. Its strategic location in Atlanta also grants it community relationships with the Centers for Disease Control (CDC), Emory University, Georgia Tech, and the Georgia Center for Medical Innovation (GCMI).
 
The company says it’s contributed to U.S. Food and Drug Administration (FDA) clearance of over 60 products over the past ten years. The deal adds T3 to its Veranex PCS France preclinical service offering, expanding the company’s global reach.
 
“The addition of T3 Labs to the Veranex family allows us to further realize our mission of unifying the entire medtech development process, from concept to commercialization,” said Pat Donnelly, CEO of Veranex. “The growth of the preclinical market, increasing regulatory requirements, and the need for efficient collaboration between clients and their product development partners make T3 Labs a strategic fit for Veranex and an incredible asset for our clients.”
 
“Joining the Veranex family enables T3 Labs to better serve the greater medtech and Science Square community,” added T3 Labs leader Sherry Farrugia. “By combining our expertise and offerings with Veranex’s existing preclinical services, we are excited about the impact we can make for our clients and the healthcare industry at large.”